Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 67Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Sarcoma 6Ovarian Neoplasms 4Brain Neoplasms 4Neoplasms 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Leiomyosarcoma 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HER2-negative Metastatic Breast Cancer 1

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × eribulin × Clear all
NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting
13 enrolled 9 charts
Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡